American Gene Technologies® is working to facilitate the fastest possible progression of AGT103-T, but it is not possible to predict availability yet. The current focus is on determining if it can functionally cure people living with HIV. Once that is established, we will move deliberately to bring it to patients in need, but the next steps will be determined based on data from the current phase 1 human trial.